Reverse transcription–PCR analysis following demethylation treatment was also extended to a fourth medulloblastoma cell line, DAOY, which did not appear to show altered expression of any of the four S100 genes examined following 5-aza CdR treatment, despite clear evidence of re-expression of the RASSF1A control transcript. This evidence concerns the gene S100B and medulloblastoma.